Merck Vorinostat 088
Trial overview
Study of Vorinostat (MK0683) an HDAC Inhibitor, or Placebo in Combination With Bortezomib in Patients With relapsed or refractory Multiple Myeloma
Inclusion criteria
- Patient is 18 years of age or older
- Patient has an established diagnosis of multiple myeloma based on the myeloma diagnostic criteria
- Patient has received at least 1 but not more than 3 prior anti-myeloma regimens and has progressive disease after the most recent treatment regimen
- Patient must have adequate organ function
Exclusion criteria
- Patient has had a prior allogeneic bone marrow transplant or plans to undergo any type of bone marrow transplantation within 4 weeks of the initiation of study therapy
- Patient has known hypersensitivity to any components of bortezomib or vorinostat
- Patient has active Hepatitis B or C, plasma cell leukemia, or is HIV positive
- Patient has had prior treatment with vorinostat or HDAC inhibitors
Contact details
Other trials currently active for Multiple Myeloma
A non-interventional observational post authorisation safety study of subjects treated with lenalidomide
Study of Vorinostat (MK0683), an HDAC Inhibitor, in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma after at least 2 prior treatment regimens
Myeloma IX is intended to be a unifying trial addressing issues in patients of all ages and providing a strategy within which to introduce new treatments as they become available. There are, however, two distinct treatment pathways. i) Intensive pathway:
For younger/fitter patients where intensive HDT with stem cell support
ii) Non-intensive pathway: considered appropriate. Although the previous MRC Myeloma VII trial, in which there was randomisation to HDT, was restricted to patients under the age of 65, it is recognised that fit patients over this age may wish to receive the more intensive treatment, and the decision with regard to which pathway to follow will be a matter for discussion between the treating clinician and the patient.
is considered appropriate.